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S U M M A R Y
Objective: To identify speciﬁc risk factors of vancomycin-induced nephrotoxicity in China, as the
relationship between vancomycin therapy (dosing and trough concentration monitoring) and
nephrotoxicity has been the subject of critical debate.
Methods: The cases of 90 critically ill patients who received vancomycin therapy in Xijing Hospital in the
northwest of China between March 2014 and January 2015 were reviewed retrospectively. Vancomycin
dosing, blood serum trough concentration, and other independent risk factors associated with
nephrotoxicity were evaluated in a multivariable model.
Results: Among the 90 critically ill patients, 59 were males; mean age was 46.3 years. The indications for
vancomycin use were methicillin-resistant Staphylococcus aureus-associated pneumonia, central
nervous system infection, and bacteremia. Clinical pharmacists prescribed weight-based dosing,
ranging from 20 to 45 mg/kg/day. Fourteen (15.6%) patients developed nephrotoxicity, with serum
creatinine elevated signiﬁcantly from a mean (standard deviation) of 90.0 (18.8) mmol/l to 133.8 (63.2)
mmol/l (p = 0.015). It was found that those with a vancomycin dosage >38 mg/kg/day (50.0% vs. 11.3%,
p = 0.004) and a vancomycin serum trough concentration >20 mg/l (57.1% vs. 12.0%, p = 0.01) were more
likely to develop nephrotoxicity.
Conclusion: The data from this study indicate that a vancomycin dosage >38 mg/kg/day and a serum
trough level >20 mg/l are both independent factors associated with the development of nephrotoxicity,
suggesting that renal function should be monitored closely during vancomycin treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Vancomycin is a tricyclic glycopeptide antibiotic that is
commonly used for the treatment of severe infections caused by
Gram-positive bacteria. It is especially indicated for methicillin-
resistant Staphylococcus aureus (MRSA), penicillin-resistant pneu-
mococci, and for patients who are allergic to penicillins and
cephalosporins.1–3 However, there is controversy regarding
vancomycin dosing, infusion methods, and serum concentration
monitoring. On the one hand, the treatment of infections in the
central nervous system (CNS) and skin require higher blood* Corresponding authors. Tel.: +86 29 84773636.
E-mail addresses: chenby@fmmu.edu.cn (B.-Y. Chen), adwen@fmmu.edu.cn
(A.-D. Wen).
http://dx.doi.org/10.1016/j.ijid.2015.06.025
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).concentrations because of the poor penetration of vancomycin into
these tissues. This pushes the effective blood concentrations close
to toxic levels, and the incidence of vancomycin-related nephro-
toxicity varies widely between 5% and 35%.4,5 In addition,
pharmacokinetic studies have generated conﬂicting evidence on
the association between serum concentration, efﬁcacy, and
nephrotoxicity.6–10 On the other hand, inadequate drug dosing
and low serum concentrations (<10 mg/l) might promote an
increase in the vancomycin minimum inhibitory concentration
(MIC) for bacteria, resulting in the development of vancomycin-
resistant strains.11–13 Indeed, a gradual increase in vancomycin
MIC in MRSA isolates has been demonstrated, which has pushed
the vancomycin dosing to a higher level.14
According to the Infectious Diseases Society of America,
clinicians can target the vancomycin serum trough concentration
at a range of 15–20 mg/l for complicated infections to improveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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dosages of less than 30 mg/kg/day seldom cause severe nephro-
toxicity.9 However, previous evidence has indicated that a serum
trough concentration >15 mg/l might be associated with increased
nephrotoxicity.15,16 A vancomycin dosing nomogram to achieve
high trough concentrations has been assessed in Taiwanese
patients.17
In China, the patients receiving vancomycin are usually
critically ill and their drug clearance rate may be altered
drastically, making them more susceptible to nephrotoxicity.
However, data regarding the associations between serum trough
concentrations, efﬁcacy, and toxicity in the northwest of China are
lacking. Therefore, the goal of the present study was to evaluate the
risk factors of nephrotoxicity in these critically ill patients
receiving vancomycin therapy, including the drug dosing regimen,
serum trough concentration, age, body weight, and incidence of
nephrotoxicity. The results of this study will provide new useful
evidence to guide vancomycin treatment in China.
2. Patients and methods
2.1. Patients
A retrospective cohort study was conducted in Xijing Hospital
of the Fourth Military Medical University between March 2014 and
January 2015. Adult patients who received vancomycin for at least
48 h were identiﬁed. Patients with renal dysfunction (receipt of
dialysis or creatinine clearance <30 ml/min), those treated with
vancomycin during the same hospital stay, those receiving
concomitant nephrotoxins (aminoglycosides, amphotericin B,
radiocontrast dye, and vasopressors), and those without available
laboratory data were excluded from the evaluation.
For all patients included in this study, the following data were
collected: age, gender, actual body weight, diagnosis, type of
infection, intensive care unit (ICU) admission, concurrent medica-
tion, vancomycin dosing, vancomycin trough concentration, and
laboratory measurements. Their medical records and related
documents were obtained with informed consent from the central
database of Xijing Hospital.
2.2. Design and data collection
Clinicians prescribed vancomycin in accordance with the
guidelines and recommendations of the Infectious Diseases Society
of America when severe MRSA infections were conﬁrmed. Actual
body weight-based dosing ranged from 20 to 45 mg/kg/day. The
most frequently used dosing in the study hospital was 1.5–2 g
every day. Vancomycin was administered by intermittent intrave-
nous infusion.
Blood samples for the measurement of the vancomycin trough
concentration were obtained within 30 min before the adminis-
tration of the ﬁfth dose of vancomycin. This trough level represents
the stable serum trough concentration of the following period.
Renal function was monitored constantly, before and during
vancomycin therapy.
No severe side effects that required the discontinuation of
vancomycin therapy occurred in this study. When the vancomycin
trough concentration was higher than 25 mg/l, the vancomycin
dosage was adjusted according to the patient’s condition. If no
methicillin-resistant strain was detected, the chemotherapy was
de-escalated to a beta-lactam antibiotic.
2.3. Deﬁnitions
Renal function was assessed by measuring the urinary
production and the serum concentration of creatinine, ureanitrogen, and cystatin. Nephrotoxicity was deﬁned as an increase
in serum creatinine (SCr) >0.5 mg/dl (44.2 mmol/l), or an increase
in SCr >50% from the baseline level for at least 2 days.18
2.4. Statistical analysis
Univariate analysis was used to compare patients who
developed nephrotoxicity with those who did not develop
nephrotoxicity in regard to the age, body weight, and other basic
characteristics. Data were analyzed with the Chi-square test.
Multivariate analysis was used to identify independent risk factors
of vancomycin-associated nephrotoxicity. IBM SPSS Statistics
version 20.0 (IBM Corp., Armonk, NY, USA) was used for the
analysis of signiﬁcant differences.
Data were presented as the mean and standard deviation (SD). A
p-value of 0.05 or less indicated a statistically signiﬁcant
difference.
3. Results
3.1. Patient characteristics
Among 172 courses of vancomycin identiﬁed, 90 patients met
the inclusion criteria. The cohort consisted of 59 men and
31 women. Their mean (SD) age was 46.3 (15.6) years and their
mean (SD) body weight was 62.4 (9.4) kg. The sources of MRSA
infection were bloodstream (52.2%), pulmonary (18.9%), CNS
(14.4%), skin/soft tissue (4.4%), genitourinary (4.4%), gastrointesti-
nal (2.2%), osteomyelitis (2.2%), and endocarditis (1.1%).
3.2. Administration of vancomycin
The median length of vancomycin therapy was 9 days. The
mean (SD) dosage was 31.3 (5.4) mg/kg/day. Thirty-four patients
were given vancomycin dosages between 20 and 30 mg/kg/day
(25.5  2.8), and 46 patients were given doses between 30 and
38 mg/kg/day (33.2  2.3). Ten patients were given >38 mg/kg/day
(40.4  1.6). The mean (SD) vancomycin serum concentration was
10.1 (5.4) mg/l. Fifty-eight patients had a mean concentration
between 5 and 10 mg/l (6.9  1.7), and 25 patients had a mean
concentration between 10 and 20 mg/l (13.5  3.0). Seven patients
had a concentration higher than 20 mg/l (23.9  2.1). There were two
deaths due to multiple organ failure. All other patients achieved
clinical cure by the time of discharge from the hospital.
3.3. Incidence of nephrotoxicity
Among 90 patients, there were two mortalities due to multiple
organ failure. A total of 14 (15.6%) patients developed nephrotoxi-
city while receiving vancomycin therapy. None of these patients
showed severe symptoms or needed dialysis. Their renal dysfunc-
tion was transient and laboratory measurements returned to
normal levels before hospital discharge.
The mean (SD) SCr of all patients prior to vancomycin treatment
was 78.9 (23.8) mmol/l. The calculated baseline mean (SD)
creatinine clearance rate was 94.8 (53.5) ml/min. After the
initiation of vancomycin treatment, the mean (SD) SCr increased
signiﬁcantly to 86.8 (38.5) mmol/l (p < 0.05). Although both ﬁgures
were within the normal range, statistically signiﬁcant changes
were observed when patients with and without nephrotoxicity
were evaluated separately.
With regard to the 14 patients who developed nephrotoxicity,
their mean (SD) baseline SCr was 90.0 (18.8) mmol/l. During
vancomycin treatment, this ﬁgure increased signiﬁcantly to 133.8
(63.2) mmol/l (p = 0.015). For the other 76 patients without
nephrotoxicity, there was no signiﬁcant change in SCr prior to and
Table 1
Characteristics of patients with and without nephrotoxicity (N = 90)a
Characteristic No nephrotoxicity
(n = 76)
Nephrotoxicity
(n = 14)
p-Value
Age, years 48.6 (15.1) 51.4 (19.1) 0.701
Body weight, kg 52.9 (9.5) 57.1 (6.7) 0.006
Treatment length, days 10.6 (4.7) 10.5 (3.1) 0.969
Dosage, mg/kg/day 30.6 (5.2) 34.9 (4.9) 0.007
Trough level, mg/l 10.7 (4.9) 14.5 (6.3) 0.184
Baseline SCr, mmol/l 76.9 (24.1) 90 (18.8) 0.065
SCr during treatment,
mmol/l
78.2 (24.1) 133.8 (63.2) 0.009
SCr, serum creatinine.
a Results are presented as the mean (standard deviation).
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respectively (p = 0.41).
The actual body weight and dosing showed signiﬁcant
differences between patients with and without nephrotoxicity.
However, in terms of the age, gender, length of vancomycin
treatment, vancomycin serum trough concentrations, and baseline
SCr levels, there were no signiﬁcant differences. The results are
presented in Table 1.
Multivariable data analysis showed that a vancomycin dosage
>38 mg/kg/day and a vancomycin serum trough level >20 mg/l
were both independent predictors of renal toxicity. The results are
shown in Table 2.
4. Discussion
In this retrospective study, 15.6% of 90 critically ill patients
developed nephrotoxicity during vancomycin treatment. It was
demonstrated that patients receiving weight-based dosages higher
than 38 mg/kg/day and with a serum trough concentration greater
than 20 mg/ml were more likely to develop nephrotoxicity. It was
also noticed that the incidence of nephrotoxicity was higher than
in previous studies that have reported standard vancomycin
dosing (30 mg/kg/day), in which this caused around 5% of patients
to develop nephrotoxicity.4,5 This might be due to the fact that
11.1% of patients were receiving dosages around 40 mg/kg/day and
all patients were in a critical state.
The relationships between vancomycin dosing, serum trough
concentrations, and efﬁcacy or nephrotoxicity have been docu-
mented by other authors.4,19–21 Vancomycin prescribed at a high
dose and an extended duration of use appear to be the risk factors
for developing nephrotoxicity.22,23 Larger doses and increased
vancomycin trough concentrations have been shown to be
involved in the occurrence of renal injury.8,24,25 For instance,
vancomycin-induced nephrotoxicity occurred when the dosing
regimen maintained the trough concentration between 15 and
20 mg/l.15,16 Han et al. also reported that a trough concentration
over 12.1 mg/l was a major risk factor for nephrotoxicity inTable 2
Multivariable analysis of independent risk factors for nephrotoxicity (N = 90)
Variable OR 95% CI p-Value
Sex female 0.903 0.623–1.308 0.764
Age 60 years 1.105 0.778–1.570 0.503
Body weight 55 kg 1.361 0.428–4.333 0.406
Dosage 38 mg/kg/day 1.474 0.994–2.185 0.004
Duration of therapy 15 days 1.621 0.72–3.359 0.152
Vancomycin trough 20 mg/l 1.345 0.963–1.879 0.010
ICU admission 1.013 0.804–1.277 >0.99
OR, odds ratio; CI, conﬁdence interval; ICU, intensive care unit.patients undergoing therapeutic vancomycin monitoring.26 The
nephrotoxicity might also be a particular matter in high-dose
vancomycin therapy for MRSA infections.27–29 Obviously, regular
monitoring of vancomycin dosing is critical for the prevention of
nephrotoxicity.30,31
The increased dosing of vancomycin treatment was supposed to
counter the gradual creeping of the vancomycin MIC in MRSA
isolates.1,14 Although weight-based vancomycin dosing has been
recommended in the guidelines,6,7,9 the association between
different dosing and nephrotoxicity is yet to be clariﬁed, especially
in the northwest area of China. From the authors’ observations,
aggressive dosages are more likely to cause nephrotoxicity.
Evidence suggests that a solution to this problem might be the
use of continuous infusion, which could replace the ﬂuctuating
concentrations with a plateau concentration of 20–25 mg/l. This
could also maximize treatment efﬁcacy and reduce nephrotoxicity.
Studies performed by DiMondi and Rafferty32 and Hutschala
et al.33 have shown that continuous infusion results in a lower rate
of nephrotoxicity developing compared with intermittent infu-
sion.32,33
Moreover, previous evidence has shown that the incidence of
vancomycin-induced nephrotoxicity may also be related to patient
age,34–37 the severity of illness,38,39 chronic kidney disease, and
methicillin-resistant pneumonia.40,41 In the present study, the
incidence of nephrotoxicity of 15.6% also implies that a critically ill
state might be a risk factor for renal toxicity with vancomycin
therapy. Among the 14 patients who developed nephrotoxicity,
10 were male and four were female, suggesting that there may also
be a gender difference in relation to the incidence of nephrotoxi-
city.
The possible mechanisms of vancomycin-induced nephrotox-
icity have also been investigated previously.42 For instance,
oxidative stress from mitochondrial superoxide production
might contribute to vancomycin-related renal injury,43,44 while
the manipulation targeting superoxide dismutase to renal tubule
cells has been shown to improve the vancomycin-induced
nephrotoxicity in rodents.45 The serum neutrophil gelatinase-
associated lipocalin could also inﬂuence renal function in
patients on vancomycin treatment,46 and the functional state
of the kidney in children might lead to susceptibility to
vancomycin toxicity.47
This study has several limitations. First, this was a retrospective
investigation of MRSA patients in only one institution. An
observation bias of the data cannot be excluded. Second, the
patients receiving vancomycin in the northwest of China were
mostly critically ill patients. Their vancomycin distribution and
clearance status could be signiﬁcantly altered, making them more
susceptible to nephrotoxicity. Last, loading doses and pharmaco-
kinetic monitoring of vancomycin have not yet been adopted in the
study institution. Multicenter controlled studies with a larger
sample are still needed to clarify the associations between dosing,
serum trough concentrations, and nephrotoxicity. This would
beneﬁt these critically ill patients by ensuring efﬁcacy and safety
during vancomycin therapy.
In conclusion, the present results suggest that vancomycin
dosing higher than 38 mg/kg/day and trough concentrations
greater than 20 mg/ml might be associated with an increased risk
of developing nephrotoxicity. These data may provide useful
evidence to instruct clinicians for evaluating the vancomycin
regimen in China.
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